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Edited by Felix WielandAbstract Two novel peptides that inhibit the intra-erythrocyte
stage of Plasmodium falciparum in vitro were identiﬁed in the
venom of the Trinidad chevron tarantula, Psalmopoeus cambrid-
gei. Psalmopeotoxin I (PcFK1) is a 33-residue peptide and
Psalmopeotoxin II (PcFK2) has 28-amino acid residues; both
have three disulﬁde bridges and belong to the Inhibitor Cystine
Knot superfamily. The cDNAs encoding both peptides were
cloned, and nucleotide sequence analysis showed that the peptides
are synthesized with typical signal peptides and pro-sequences
that are cleaved at a basic doublet before secretion of the mature
peptides. The IC5O of PcFK1 for inhibiting P. falciparum growth
was 1.59% 1.15 lM and that of PcFK2 was 1.15% 0.95 lM.
PcFK1 was adsorbed strongly to uninfected erythrocytes, but
PcFK2 was not. Neither peptide has signiﬁcant hemolytic activity
at 10 lM. Electrophysiological recordings in isolated frog and
mouse neuromuscular preparations revealed that the peptides (at
up to 9.3 lM) do not aﬀect neuromuscular transmission or quantal
transmitter release. PcFK1 and PcFK2 do not aﬀect the growth or
viability of human epithelial cells, nor do they have any antifungal
or antibacterial activity at 20 lM. Thus, PcFK1 and PcFK2 seem
to interact speciﬁcally with infected erythrocytes. They could
therefore be promising tools for antimalaria research and be the
basis for the rational development of antimalarial drugs.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Animal venoms are valuable sources of novel pharmaco-
logical tools whose speciﬁc actions are useful for characterizing
their receptors. Hundreds of toxins from snakes, scorpions,
spiders and marine invertebrates with a range of pharmaco-
logical activities have all been characterized [1–3].
Spider venoms contain a wide spectrum of biologically ac-
tive substances, which selectively target a variety of vital
physiological functions in both insects and mammals (for re-
view, see [4,5]). The spider toxins are ‘‘short’’ polypeptides
with molecular mass of 3–8 kDa and a structure that is held
together by several disulﬁde bonds. There are two main groups
of these peptides, the neurotoxins that target neurone recep-
tors, neurone ions channels or presynaptic proteins involved in
neurotransmitter release, and the non-neurotoxic peptides,
such as necrotic peptides and antimicrobial peptides (for a
review, see [6]). Recent studies have characterized the venoms
of the genuses Brachypelma, Pterinochilus and Theraphosa [7–
10]. Several peptides that inhibit atrial ﬁbrillation [11], block
the Kv2 and Kv4 subfamilies of voltage-dependent potassium
channels [12,13], or multiple sodium channels [14], and proton-
gated sodium channels [15] have been recently isolated. Al-
though spider toxins bind to their receptors with high aﬃnity,
speciﬁcity, and selectivity, little is known about them and little
work has been done to develop these toxins for therapeutic
use.
Malaria is one of the most serious and widespread parasitic
diseases in the world. There are an estimated 300–500 million
clinical cases each year, and 1–1.5 million people die each year
due to malaria, mainly young children (for a review, see [16]).
The causative agent of malaria, an intracellular protozoan of
the genus Plasmodium, spends much of its life cycle within the
host erythrocyte. Plasmodium falciparum is the most virulent
of the four species of Plasmodium that infect humans. Theation of European Biochemical Societies.
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drugs means that new chemotherapeutic approaches are ur-
gently needed [17]. Classical strategies are based on modifying
known antimalarial drugs, while others that seek new biolog-
ical targets require a better understanding of the Plasmodium
biology, life cycle and interaction with its host [18]. Various
plant and animal substances have emerged recently as inter-
esting tools for exploring new potential antimalarial targets
[19–22].
As part of a general screening for antimalarial drugs, we
investigated the potential of toxins from Psalmopoeus cam-
bridgei, the Trinidad chevron tarantula. This report describes
two novel peptides (PcFK1 and PcFK2, Psalmopoeus cam-
bridgei F alciparum killer) that possess great antiplasmodial
activity against the intra-erythrocyte stage of P. falciparum
in vitro, but do not lyse erythrocytes or nucleated mammalian
cells and do not inhibit neuromuscular function, despite their
structural similarity to known neurotoxins.2. Materials and methods
2.1. Venom and toxin puriﬁcation
Psalmopoeus cambridgei (Araneae theraphosidae) venom was ob-
tained by electrical stimulation of venom glands. The crude venom was
centrifuged (5000 g, 4 C, 20 min), ﬁltered through 0.45-lm micro-
ﬁlters (SJHVL04NS, 4-mm diameter, Millipore) and stored at )20 C.
It was then diluted twofold in 10% acetic acid and fractionated by
reverse-phase high pressure liquid chromatography (RP-HPLC) on a
C18 column (Supelcosil, 5 lm, 4.6 250 mm, Supelco) eluted with a
linear 0–60% gradient of acetonitrile in 0.1% aqueous triﬂuoroacetic
acid (TFA) for 70 min (ﬂow rate: 0.75 ml/min). Fractions (0.75 ml)
were collected and freeze-dried. The peptides were dissolved in RPMI
1640 (Life Technologies, Inc.) and screened for antiplasmodial activity.
The peptides in active fractions were further puriﬁed by RP-HPLC on
the same column with a gradient of 35–65% of solvent B (A, 0.1% TFA
in water; B, 60% acetonitrile and 0.1% TFA in water). A total of 90 ll
of venom was puriﬁed as six 15 ll batches. All solvents used were of
HPLC grade. Chromatography was done on a Waters IonSep HPLC
system coupled to a model 994 diode array detector and elution was
monitored at 220 nm.
2.2. Amino acid sequence analysis
Sequences were determined on a gas phase automatic protein se-
quencer (Applied Biosystems 476A gas phase peptide sequanator).
Phenylthiohydantoin-derivatives were detected with an on-line Ap-
plied Biosystems 120A analyzer. Data collection and analysis were
performed with an Applied Biosystems 900A module calibrated with
32.5 pmol of phenylthiohydantoin-derivative standards.
Homologies of the peptide sequences were determined using the
‘‘search for short nearly exact matches’’ tool of the BLAST server at
NCBI (http://www.ncbi.nlm.nih.gov) and non-redundant databases.
The ‘‘Blast 2 Sequences’’ tool (http://embnet.cifn.unam.mx/blast/
wblast2.html) was used to search for homologies between Psalmo-
peotoxins and speciﬁc published sequences when necessary. Percent-
ages of similarity and multiple alignments were computed using the
ClustalW software and phylogenetic trees were constructed using the
TreeView program.
2.3. Mass spectrometry analysis
The mass spectra of positive ions were recorded in reﬂectron mode
with a single stage reﬂectron matrix-assisted laser desorption/ioniza-
tion time-of-ﬂight (MALDI-TOF) mass spectrometer (Voyager DE-
PRO; PerSeptive Biosystems, Inc., Framingham, MA) equipped with a
delayed extraction device. The delayed extraction time was set at 100
ns. A saturated solution of a-cyano-4-hydroxycinnamic acid in 50%
acetonitrile and 0.1% TFA was used as matrix for all MALDI exper-
iments. Spectra were calibrated using close external standard peptide
mixtures.2.4. Cloning
Total RNAs were extracted from P. cambridgei venom glands frozen
in liquid nitrogen, powdered and homogenized, as described by
Chomczynski and Sacchi [23]. Poly(A)þ RNAs were puriﬁed using the
Invitrogen Micro-FastTrack kit, and a cDNA library was constructed
[24], using a standard procedure with a NotI adaptor in the cDNA
synthesis step and a SalI adaptor for cloning into the pSPORT1 vector
(Life Technologies, Inc.). Recombinant plasmids were prepared by
transformation of JM109 competent Escherichia coli cells. The quality
of the cDNA library was estimated by determining the size of the inserts
in a random sample of 20 plasmids linearized by digestion with MluI.
A combination of 30-RACE (Rapid Ampliﬁcation of cDNA End)
and nested-PCR steps was used to screen the cDNA library for se-
quences encoding PcFK. The reaction was performed using an anti-
sense universal primer (primer UP: 50-TAAAACGACGGCCAGT-30)
and a sense degenerated primer corresponding to the amino acids
HDNCVYV of PcFK1 (primer PSA-I: 50-CAYGAYAAYTGYG-
TKTAYGT-30) and the amino acids PAGKTCV of PcFK2 (primer
PSA-II: 50-CCKGCKGGRAARACKTGYGT-30) under the following
conditions: 94 C for 240 s, followed by 30 cycles of 94 C for 40 s, 56
C for 30 s, and 72 C for 60 s. An aliquot of the ﬁrst round of PCR
was used as template for nested-PCR, using an antisense universal
primer and a sense degenerated primer corresponding to the amino
acids YVPAQNPC of PcFK1 (primer Nest-PSA-I: 50-TAY-
GTKCCKGCKCARAAYCCKTGY-30) and the amino acids
TCVRGPMR of PcFK2 (primer 2: 50-TGYGTTKMGKGGKCCK-
ATGMG-30) under the following conditions: 94 C for 240 s, followed
by 25 cycles of 94 C for 40 s, 52 C for 30 s, and 72 C for 60 s. At the
end of the last cycle, the sample was incubated at 72 C for a further 5
min and separated by electrophoresis in 1.2% agarose gels. DNA
fragments were excised from the gel and puriﬁed using the Qiaquick gel
extraction kit (Qiagen). The PCR product was cloned in the pGEMT-
Easy vector system (Promega). Nucleotide sequences were analyzed by
the dideoxy chain termination technique in a double-stranded
pGEMT-Easy vector using the BigDye ﬂuorescent labeling kit and an
ABI 377 automatic sequencer. We used an antisense T7 primer (primer
T7: 50-TAATACGACTCACTATAGGGA-30) and a 30 sense gene-
speciﬁc primer deducted from the 50 cDNA of PcFK1 (primer 3:
50-TTTCTGTGCTTTTGTTGCT-30) or PcFK2 (primer 4: 50-CTCA-
TTAACTTCGTTTCATCAGGTAC-30) to determine the sequences of
the 50-end of the Psalmopeotoxins. The following thermal cycle proﬁle
was used for the RACE-PCRs: 94 C for 240 s, 25 cycles of 94 C for
40 s, annealing at 54 C for 30 s and 72 C for 60 s, and a ﬁnal ex-
tension step of 72 C for 5 min. PCR products were puriﬁed with the
Qiaquick kit (Qiagen), cloned in pGEMT-Easy vector (Promega), and
sequenced as above.
2.5. Structural modeling
We prepared a structural model of PcFK1 and PcFK2 using a
combination of dedicated bioinformatic tools (TITO [25], Fugue [26],
and 3D-PSSM [27]) on the meta-server at the CBS, Montpellier,
France [28] (http://bioserv.cbs.cnrs.fr/).
2.6. Eﬀect of PcFK1 and PcFK2 on parasite viability
The Columbian strain FcB1 of P. falciparum was used in all exper-
iments. The parasites were cultured [29] in human red blood cells in
complete medium and a 3% CO2, 6% O2, and 91% N2 atmosphere. The
complete medium was RPMI 1640 (Life Technologies, Inc.) containing
25 mM HEPES, 11 mM glucose, 27.5 mM NaHCO3, 100 IU/ml
penicillin, 100 lg/ml streptomycin, and 7% (v/v) autologous heat-in-
activated human serum. The in vitro life cycle of the FcB1 strain was
48 h under our culture conditions.
Increasing concentrations of the peptides in complete medium were
distributed (100 ll/well) in a 96-microwell plate for screening anti-
plasmodial peptides and the dose–response assay. An asynchronous
culture of P. falciparum at 1–1.5% parasitemia and 4% hematocrit in
complete medium was added to each well (100 ll/well), and the cells
were allowed to grow in a candle jar system for 24 h. [3H]hypoxanthine
was added (0.5 lCi/well) and incubation continued for a further 24 h.
The red blood cells were broken by freeze-thawing and harvested on
ﬁlters. The dried ﬁlters were submerged in a liquid scintillation mixture
(OptiScint Hisafe) and counted in a 1450 Microbeta counter (Wallac,
Perkin–Elmer). Inhibition of growth was calculated from the radio-
activity of the parasites (incorporated into nucleic acids). The IC50 was
determined according to Desjardins et al. [30].
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concentration of PcFK1 and PcFK2 that caused 100% parasite inhi-
bition to distinguish between non-speciﬁc hemolysis due to each toxin
and their antiplasmodial eﬀects. Hemolytic activity was correlated to
hemoglobin leakage into the suspension and monitored by measuring
the absorbance of the supernatant at 540 nm. One hundred percent
hemoglobin release was determined on a lysate prepared by repeated
freeze-thawing of the corresponding batch of red blood cells.
Toxins were suspended (at 20 lM) in 200 ll complete medium with
2 107 RBCs and incubated for 90 min at 37 C to determine whether
PcFK1 and PcFK2 bound to uninfected erythrocytes. Uninfected
erythrocytes were then removed by centrifugation and the culture su-
pernatant was tested for its capacity to inhibit the growth of P. falci-
parum in dose–response assays.
2.7. Analysis of PcFK1 and PcFK2 cytotoxicity
The bactericidal action of PcFK1 and PcFK2 was assayed using wild
type strains of E. coli (Gram()), MG1655) and Bacillus subtilis
(Gram(+), Mahrburg 168) plated on solid rich media (LB 2% agar).
PcFK1 and PcFK2 (0.1–20 lM) were applied to the plates as 10 ll dots
to allow ring inhibition of the bacterial growth. The plates were
examined after incubation for 48 h at 37 C.
The fungicidal action of PcFK1 and PcFK2 was evaluated using
wild type strains of Saccharomyces cerevisiae (BY4741) and Candida
albicans (SC5314) plated on solid rich media (YPD 2% agar). PcFK1
and PcFK2 (0.1–20 lM) were applied to the plates as 10 ll dots to
allow ring inhibition of the yeast growth. The plates were examined
after incubation for 48 h at 30 C.
The eﬀects of PcFK1 and PcFK2 on mammalian cells were tested
using HeLa 229 epithelial cells (obtained from the American Type
Culture Collection, Manassas, VA). The HeLa cells were cultivated in
Dulbecco’s modiﬁed minimal essential medium (DMEM) with 2 mM
Glutamax-1 (Life Technologies, Inc.), 10% heat-inactivated fetal calf
serum, 2 mM glutamine, 100 lg/ml streptomycin and 100 U/ml peni-
cillin. Conﬂuent HeLa cells (6 104 cells/well) were incubated with the
indicated concentrations of PcFK1 and PcFK2 in DMEM for 48 h.
Cell death was measured by cytoﬂuorimetry using double-staining of
cells with propidium iodide (PI) and Annexin-V-FITC (Roche Diag-
nostic, Mannheim, Germany) as previously described [31]. Cells trea-
ted with 1 lM staurosporine were used as positive controls. Each
experiment was repeated at least three times on separate days.2.8. Electrophysiological recordings on isolated neuromuscular
preparations
Cutaneous pectoris nerve–muscle preparations were removed from
double-pithed male frogs (Rana esculenta) weighing 20–25 g. Isolated
nerve–muscle preparations were suﬀused with standard frog physio-
logical saline (115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl2, and 5 mM
HEPES, pH 7.25). In some experiments, excitation–contraction was
uncoupled by treating preparations with 2 M formamide for 21 min
[32,33]. Left and right hemidiaphragm muscles with their associated
phrenic nerves were isolated from Swiss Webster mice (20–25 g) killed
by dislocation of the cervical vertebrae followed by immediate exsan-
guination. Each hemidiaphragm was mounted in a Rhodorsil-lined
organ bath (2 ml volume) superfused with physiological saline (154 mM
NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 5 mM HEPES buﬀer,
and 11 mM glucose). The solution gassed with pure O2 had a pH value
of 7.4. Membrane potentials and synaptic potentials were recorded with
intracellular microelectrodes ﬁlled with 3 M KCl (8–12 MX resistance)
at room temperature (22–24 C) using an axoclamp 2B system (Axon
Instruments, Union City, CA) and conventional techniques [33]. The
motor nerve of the isolated neuromuscular preparation was stimulated
via a suction microelectrode, and recordings were made continuously
before and throughout application of the peptides tested.3. Results
3.1. Isolation, puriﬁcation and characterization of
Psalmopeotoxin I and Psalmopeotoxin II
Analysis of the fractions obtained by RP-HPLC of the crude
P. cambridgei venom by mass spectrometry (manuscript in
preparation) revealed the presence of at least 150 individualpeptides with masses of 1000–6000 Da. Many of them con-
tained multiple disulﬁde bonds, as determined by comparing
native and reduced peptides.
Screening for antiplasmodial activity revealed the presence
of two active fractions (Fig. 1A). The active peptides in these
fractions were puriﬁed to homogeneity by chromatography on
reverse-phase columns with an appropriate elution gradient
(Fig. 1B and D). The purity of each peptide was assessed by
MALDI-TOF (Fig. 1C and E), ESI-Qq-TOF mass analysis,
amino-acid composition and Edman sequential N-terminal
analysis. The two active peptides were named Psalmopeotoxin
I (PcFK1) and Psalmopeotoxin II (PcFK2).
PcFK1 contained 33 amino acid residues and PcFK2 con-
tained 28. They both had six cysteines forming three disulﬁde
bridges. Their full sequences were established by N-terminal
Edman degradation of the reduced alkylated toxins (Fig. 2A).
The calculated molecular mass (3616.69 Da) of PcFK1 was
consistent with the measured molecular mass (3615.60 Da,
Fig. 1C), but the 1 Da diﬀerence mass suggested an amidated
carboxylic acid at the C-terminus. The calculated molecular
mass (2948.34 Da) of PcFK2 was consistent with the measured
molecular mass (2948.30 Da, Fig. 1E), suggesting a free car-
boxylic acid at the C-terminus.
The amino acid sequence of PcFK1 showed only 35%
identity with PcFK2, but the two peptides had identical di-
sulﬁde bridge patterns (Fig. 2A). The conserved residues in-
cluded two prolines (Pro13 and Pro17) that could play critical
roles in the structure of the peptides. A database search for
similar amino acid sequences revealed that PcFK1 is 48%
identical to tachystatin A, a 44 residue antimicrobial peptide
found in the hemocytes of the horseshoe crab (Tachypleus
tridentatus) [34]. PcFK2 is very similar (60% identity) to a
peptide found in the venom of an American tarantula (Eu-
rypelma californicum) [35]. The Eurypelma sequence missed
one cysteine residue, perhaps due to an error in sequencing. No
speciﬁc activity has been reported for the Eurypelma toxin.
PcFK2 is also very similar (41% identity) to the omega-cono-
toxin SVIA of Conus striatus venom, which binds to and
blocks voltage-sensitive calcium channels on presynaptic
membranes [36] (Fig. 2B and C).
3.2. Comparative analysis of PcFK1 and PcFK2 cDNAs
Several thousand E. coli colonies were obtained by trans-
formation with the cDNA library constructed from 0.4 lg of
poly(A)þ RNA obtained from seven venom glands. A random
sampling of 20 individual colonies allowed the characterization
of all inserts with diﬀerent sizes, ranging from 100 bp to more
than 800 bp. The library was therefore representative of the
sequences encoding short peptide toxins. We then character-
ized the cDNAs encoding PcFK1 and PcFK2 obtained from
the cDNA library by a combination of 30-RACE, nested-PCR
and 50-RACE. The nucleotide sequence of PcFK1 was quite
unlike that encoding PcFK2. The cDNAs were 459 and 392 bp
long with a 69/80 bp 50-UTR, the coding sequence, and a 129/
114 bp 30-UTR. A putative polyadenylation signal (AATAAA)
was found 17 nt upstream of the poly(A) tail of PcFK1 and 14
nt upstream of the poly(A) tail of PcFK2 cDNA. The pre-
cursors of PcFK1 and PcFK2 deduced from their nucleotide
sequences contained a putative signal peptide (21 residues in
PcFK1 and 19 residues in PcFK2), with a basic residue in their
N-termini and a hydrophobic central core. Each also had a
propeptide (30 residues in PcFK1 and 19 residues in PcFK2)
Fig. 1. Puriﬁcation and characterization of PcFK1 and PcFK2. (A) RP-HPLC separation of crude P. cambridgei venom with a linear 0–60% gradient
of acetonitrile in 0.1% aqueous TFA (70 min at 0.75 ml/min). Arrows indicate the fractions containing PcFK2 [35] and PcFK1 [45]. (B)–(E) RP-
HPLC and MALDI-TOF analysis of puriﬁed PcFK1 (B, C) and PcFK2 (D, E); RP-HPLC using a 35–65% gradient of 60% acetonitrile (80 min at
0.75 ml/min) [M+2Hþ] corresponds to doubly charged ions.
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(Lys-Arg in the PcFK1 precursor, Arg-Arg in the PcFK2
precursor). The third part was the sequence of the mature
toxin (Fig. 3A and B).
3.3. Structural modeling
The structural models of PcFK1 and PcFK2, generated us-
ing a combination of dedicated bioinformatic tools, were used
to compute the most likely structure by homology modeling of
both peptides with the same entry of the PDB database 1NIX,
as a support. 1NIX reports the 2D 1H NMR solution structure
of hainantoxin-I (HnTx-I), a peptide from the venom ofOrnithoctonus (Selenocosmia) hainana, a chinese bird spider
[37]. The structures diﬀered mainly in the conformation of the
loop formed by residues 9–15 (Fig. 4). The two-residue inser-
tion between CIV and CV had little eﬀect on the overall
structure of the peptides.
3.4. Antiplasmodial activity of PcFK1 and PcFK2
Both PcFK1 and PcFK2 inhibited the development of P.
falciparum in erythrocytes in vitro, with IC50 of 1.59 1.15 and
1.15 0.95 lM, respectively. Although the IC50 values of
PcFK1 and PcFK2 could be inﬂuenced by experimental pa-
rameters, such as the source of serum and red blood cells, and/
Fig. 2. Sequence alignment of PcFK1 and PcFK2. (A) Sequence alignment of PcFK1 and PcFK2 (*, C-terminal amidation). (B) Multiple alignment
with structural family of inhibitor cystine knot peptides, on the six conserved half-cystine residues; conserved residues are in black boxes; homol-
ogous regions are gray. Sequences from NCBI (http://www.ncbi.nlm.nih.gov): tachystatin A; 1CIXA, E. californicum; S07826, x-conoTxSVIA;
AAB23763, AcTx-Hvi; 1AXH, x-AcTx-Hv1a; P56207, x-AcTx-Hv2a; P82852, AptoTxVII; B44007, CvTx-II; P82601, GsMTx-2; 1LUPA, GsMTx-
4; A59371, x-GsTxSIA; AAB28031, HaTx1; P56852, HnTx-I; P83591, HpTx2; P58426, HwTx-I; A37479, HwTx-IV; P83303, PcTx1; 1LMM, Protein
5; AAB32862, SNX482; P56854. All peptides except tachystatin A and x-conoTxSVIA are from spider venoms. (C) Phylogenetic tree of cystine knot
peptides based on a ClustalW multiple alignment.
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they were always in the low micromolar range. Dermaseptin
B2, a 45-residue antimicrobial peptide from frog skin, was
used as control in dose–response assays to assess the toxic
speciﬁcity of the peptides. At the highest concentration tested
(20 lM), dermaseptin B2 had little (25%) or no eﬀect on the
viability of P. falciparum (not shown). We determined whether
toxicity was due to the unspeciﬁc lysis of erythrocytes bymeasuring the capacity of PcFK1 and PcFK2 to hemolyse
uninfected RBCs. Neither PcFK1 nor PcFK2 had any hemo-
lytic activity at 10 lM, the highest concentration tested, with
each peptide lysing <1.5% of the erythrocytes.
3.5. Depletion of PcFK1, but not PcFK2, by normal RBCs
We examined the possibility that the Plasmodium-speciﬁc
toxicity of PcFK1 and PcFK2 resulted from their non-speciﬁc
Fig. 3. Nucleotide sequences of cDNAs encoding precursors of PcFK1 (A) and PcFK2 (B) from P. cambridgei. The putative signal peptide is un-
derlined with dots and the propeptide is underlined. Gray boxes indicate a basic doublet. The nucleotide sequences of the matured PcFK1 and
PcFK2 are underlined in bold. A potential polyadenylation signal AATAAA is underlined twice.
Fig. 4. The three-dimensional structure model of PcFK1 (A) and
PcFK2 (B) based on the NMR structure of HnTx-I.
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90 min with uninfected erythrocytes, and the culture super-
natant was then tested for its capacity to inhibit parasite
growth. Each experiment was repeated twice with similar
qualitative results. The results from a representative experi-
ment are shown in Fig. 5. The adsorptions of PcFK1 and
PcFK2 diﬀered considerably. The dose–response curve of P.
falciparum growth inhibition by PcFK1 was shifted to a higher
apparent IC50 that reﬂected a loss of peptide after incubation
with normal RBCs (the actual concentration of the peptide is
lower than the theoretical maximum concentration reported
on the X-axis of the plot in Fig. 5A). If the IC50 was not al-
tered by its incubation with the RBC, then more than 85% of
PcFK1 remained bound to the normal RBCs (IC
app
50 ¼ 0.74
lM before incubation with RBC and 6.37 lM after incuba-
tion) (Fig. 5A). The IC50 of PcFK2 did not change signiﬁ-cantly (0.28 lM before incubation with RBC and 0.46 lM
afterwards, Fig. 5B). The IC50 of PcFK1 was also slightly
higher after incubation in RPMI containing 8% serum but no
erythrocytes (Fig. 5A), indicating that part of the toxin is
probably lost through electrostatic and/or hydrophobic in-
teractions with plastic wells or components of the medium.
Thus PcFK2, unlike PcFK1, binds selectively to parasitized
erythrocytes. Conversely, the toxic, active concentration of
PcFK1 determined in previous dose–response assays could be
an overestimate.
3.6. Eﬀect of PcFK1 and PcFK2 on bacteria, yeast and
mammalian cells
The speciﬁcities of PcFK1 and PcFK2 for P. falciparum were
tested by measuring their eﬀects on bacteria, yeast and mam-
malian cells. The growth of neither Gram(+) nor Gram())
bacteria, nor that of yeast grown on solid media in antibio-
gram-like disk assays was inhibited by toxin concentrations up
to 20 lM (data not shown). Neither were PcFK1 or PcFK2
toxic for HeLa cells in culture at concentrations up to 50 lM
(PcFK1; 20 lM for PcFK2), as measured by FACS analysis of
PI and annexin-V-FITC labeled cells (data not shown).
3.7. Eﬀect of PcFK1 and PcFK2 on neuromuscular transmission
We tested the eﬀects of the peptides on isolated frog and
mouse neuromuscular preparations to determine whether
PcFK1 and PcFK2 altered voltage-dependent ion channels.
Neither PcFK1 nor PcFK2 (0.1–9.3 lM) had any signiﬁcant
eﬀect on various electrophysiological parameters related to
neuromuscular transmission (nerve conduction through in-
tramuscular axons, latency of endplate potentials, and
threshold potential for action potential generation in muscle
ﬁbers). Thus the peptides, in the concentration range used,
have no eﬀect on nerve and muscle excitability and conduction.
PcFK1 and PcFK2 also had no eﬀect on spontaneous or
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Fig. 5. Dose–response curves for PcFK1 and PcFK2 acting on P.
falciparum viability. PcFK1 (20 lM) (A) and PcFK2 (20 lM) (B) in
RPMI plus 8% serum were incubated with 2 107 erythrocytes () or
without erythrocytes (j) for 90 min at 37 C in a 96-well microplate.
The supernatants were then assayed for their ability to inhibit the
development of the FcB1 strain of P. falciparum in erythrocytes. De-
creasing concentrations of the supernatants in RPMI plus serum were
incubated with a 1.5% parasitemia and 2% hematocrit asynchronous
culture of the parasite in a 96-well plate for 24 h. 0.5 lCi [3H]hypo-
xanthine was then added to each well and incubation continued for a
further 24 h. The cells were harvested on ﬁlters and broken by freeze-
thawing. [3H]hypoxanthine incorporation was measured in a 1450
Microbeta counter (Wallac). 100% incorporation was measured in the
absence of peptide. Dose–response control without incubation (n).
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potentials and endplate potentials), indicating that synaptic
transmission is unaﬀected by the peptides. In contrast to
PcFK1 and PcFK2, in the presence of the inorganic ion Cd2þ,
a non-speciﬁc voltage-dependent calcium channel blocker,
nerve-evoked transmitter release was unable to trigger muscle
action potentials (data not shown). Similarly, PcFK1 and
PcFK2 had no eﬀect on mouse hemidiaphragm preparations
(data not shown).4. Discussion
Our search for novel antimalarial peptides led us to investi-
gate the toxins in tarantula venom. We have isolated and
characterized two novel peptides, PcFK1 and PcFK2, that in-
hibit the growth of P. falciparum in erythrocytes. PcFK1 and
PcFK2 are both cystine knot-containing peptides, and theirmolecular scaﬀolds are probably similar to those of conotoxins
and spider toxins. The general structures of the precursors of
PcFK1 andPcFK2, deduced from their nucleotide sequence, are
very similar to those of the sequences encoding many secreted
peptide toxins from spiders, scorpions and other invertebrates
(for a review, see [4]). Both are composed of a putative signal
peptide (21 and 19 residues) with a basic residue within their N-
termini and a hydrophobic central core; a propeptide rich in
acidic residues ending with a basic doublet (Lys-Arg in the
PcFK1 precursor, Arg-Arg in the PcFK2 precursor) that is
usually the target of a speciﬁc processing endopeptidase; and the
sequence of the mature toxin. Although this peptidase usually
cleaves the propeptide at the C-terminus of the basic doublet (as
found in the PcFK1 sequence), it cleaves the precursor of PcFK2
within the doublet. Native PcFK1 has 33 residues, whereas the
mature peptide deduced from the nucleotide sequence has two
extra residues, Gly-Arg, in the C-terminus of PcFK1. This fea-
ture is found in many precursors of amidated peptides [38,39].
The Arg residue is probably removed in the processing step by a
basic residue-speciﬁc carboxypeptidase, after which the re-
maining Gly-extended peptide is converted into a des-Gly pep-
tide amine by a-amidation [40].
PcFK1 is very much like tachystatin A, a 44 residue anti-
microbial peptide from the hemocytes of the horseshoe crab
(Tachypleus tridentatus) [34]. This peptide belongs to the x-
agatoxin IVA structural family of P-type calcium channel
antagonists [41]. Our antiplasmodial dose–response assays
with x-agatoxin IVA showed no parasite killing at concen-
trations as high as 51 lM (unpublished results). However, the
antimicrobial activity of tachystatin A is not due to its eﬀect on
ionic channels, but due to its binding to chitin [34]. PcFK1
lacks two essential features of tachystatin A – a conserved
phenylalanine residue between CysI and CysII involved in the
binding of tachystatin A to chitin and two large loops between
strands 1 and 3 – making it unlikely that the two peptides act
via similar mechanisms.
Like tachystatin A, PcFK1 and PcFK2 do not inhibit volt-
age-dependent ion channels, as determined in our electro-
physiological studies on isolated frog and mouse
neuromuscular preparations. However, although the activity
of tachystatin A was ascribed to its chitin-binding properties,
neither PcFK1 nor PcFK2 inhibit the growth of yeast – neither
S. cerevisiae nor C. albicans. The peptides also have no eﬀect
on the growth of bacteria such as B. subtilis or E. coli. This
raises the question of how PcFK1 and PcFK2 act on P. fal-
ciparum. The best characterized antiplasmodial peptide is
dermaseptin S4, a 28-residue peptide from the skin of a frog
(Phyllomedusa genus) [42]. Dermaseptin S4 (IC50 of 0.3–2.2
lM) eﬃciently inhibits the growth of Plasmodium, but it de-
forms the infected red blood cells due to its high hemolytic
activity [21]. PcFK1 and PcFK2 cause no swelling or shrinking
of the red blood cells. This characteristic of PcFK1 and PcFK2
is very interesting considering that the most potent antiplas-
modial dermaseptin S4 derivatives (IC50 of 0.2–7.7 lM) still
have great hemolytic activity [19,20]. Other defensin-like pep-
tides seem to act via hemolysis [43,44], and derivatives of
gramicidin A inhibit Plasmodium growth by stimulating pore-
formation, leading to the leakage of intracellular ions through
the erythrocyte membrane [45,46]. Thus, the next step towards
a better understanding of how PcFK1 and PcFK2 act will be
to identify the targets of these peptides in the infected red
blood cells. Our initial structural models of the two peptides
116 S.-J. Choi et al. / FEBS Letters 572 (2004) 109–117will help address this question. All ICK peptides usually have
similar overall folding and disulﬁde bond patterns, but their
speciﬁcities and selectivities rely on subtle variations in the
charge, hydrophobicity and/or electrostatic potential distri-
butions. We used bioinformatic search engines to look for
sequence and structure features that contain all these param-
eters [28]. Inputting the PcFK1 and PcFK2 primary sequences
led to the selection of the support structure of HnTx-I, a so-
dium channel inhibitor [37], suggesting that the peptides share
several structural features although their sequences are quite
dissimilar. This does not demonstrate that PcFK1 and PcFK2
have the same molecular target. Indeed, our data show at least
one clear diﬀerence in the behavior of the peptides towards
erythrocytes. PcFK2 interacts selectively with infected RBCs,
while PcFK1 also binds to healthy erythrocytes. This may be
because they act diﬀerently, as PcFK1 is more hydrophobic
than PcFK2. Its adsorption to RBCs may thus be based on
hydrophobic interactions with the lipid bilayer of the eryth-
rocyte membrane. Nonetheless, PcFK1 is not hemolytic, so the
interactions do not alter the permeability of the membrane.
Another possibility is that PcFK1 may interact with a speciﬁc
receptor on the RBC membrane, which could be an ion
channel whose function is not critical for the normal structure
or function of the RBC. Such speciﬁc ion channels might play
a critical role in malaria-infected erythrocytes, because of the
importance of the balance between translocation via transport
pumps and leakage of Naþ and Kþ [47]. The speciﬁc interac-
tion of PcFK2 with infected erythrocytes raises several ques-
tions. PcFK2 may target the same receptor as PcFK1 but react
with a diﬀerent site that is unmasked in the infected RBC.
PcFK2 and PcFK1 might also have diﬀerent targets. PcFK2
may bind to a parasite protein targeted to the RBC membrane
or a protein that is already present on healthy RBC, but is
cryptic or inactive until activated by infection [48]. It is also
possible that PcFK1 and PcFK2 enter the infected erythro-
cytes, aﬀect the parasite membrane and interfere with parasite
growth. However they act, the unique biochemical features of
PcFK1 and PcFK2, their ability to inhibit the growth of
Plasmodium, and their lack of hemolytic, cytotoxic or neuro-
toxic activity in mammalian systems make these peptides
promising tools for malaria research and fascinating structures
of peptidomimetics in the preparation of antiparasitic agents.
Their activities on other strains of P. falciparum and other
Plasmodium species will now be tested.
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